^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)

    i
    Other names: UGT2B15, UDP Glucuronosyltransferase Family 2 Member B15, UDP-Glucuronosyltransferase 2B15, UDP-Glucuronosyltransferase 2B8, UDPGT 2B8, UGT2B8, HLUG4, Uridine Diphosphate Glucuronosyltransferase 2 Family, Member B8, Uridine Diphosphate Glycosyltransferase 2 Family, Member B15, UDP Glucuronosyltransferase 2 Family, Polypeptide B15, UDP Glycosyltransferase 2 Family, Polypeptide B15, UDP Glucuronosyltransferase 2 Family, Member 15, UDP Glucuronosyltransferase 2 Family, Member B8, UDP-Glucuronyltransferase, Family 2, Beta-15, UDP Gycosyltransferase 2 Family, Member B15, UDP-Glucuronosyltransferase UGT2B15, UDP Glycosyltransferase 2B15, UDPGT 2B15, UDPGT2B15, UDPGTh-3, UDPGTH3
    Associations

    News

    Trials
    27d
    Comparative Proteomics Of Hepatocytes And Hepatic Cell Lines Using Swath-MS Reveals Significant Variations In Proteins Involved In Energy, Lipid, And Xenobiotic Metabolism. (PubMed, Curr Drug Metab)
    This study highlights the potential of untargeted global proteomics in detecting differences in protein expression among various hepatic cell lines and provides a comprehensive database to inform the choice of the cell line in future studies.
    Preclinical • Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • UGT1A6 (UDP Glucuronosyltransferase Family 1 Member A6) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15) • UGT1A3 (UDP Glucuronosyltransferase Family 1 Member A3)
    29d
    Remodeling of androgen metabolism network mediated by UGT2B: a new perspective on treatment resistance in prostate cancer. (PubMed, Eur J Pharmacol)
    This article systematically explores the association between the UGT2B subfamily and hormone-dependent prostate cancer, covering various aspects such as gene function, regulatory mechanisms, disease progression, and diagnosis. It elucidates the different roles of UGT2B genes and reveals their significant potential in being developed into biomarkers and therapeutic targets, paving the way for improvements in precision medicine for prostate cancer.
    Review • Journal
    |
    UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15) • UGT2B17 (UDP Glucuronosyltransferase Family 2 Member B17)
    1m
    High Risk of Drug-Drug Interactions Caused by Pexidartinib via UDP-Glucuronosyltransferases Inhibition. (PubMed, Chem Res Toxicol)
    The results of in vitro-in vivo extrapolation (IVIVE) indicated that coadministration of pexidartinib at a clinically approved dose (400 mg twice daily) with the drugs primarily cleared by UGT1A1, UGT1A6, UGT1A7, UGT1A9, and UGT2B15 would result in a higher risk of DDI. In summary, our results provide useful information for the mechanism underlying pexidartinib-induced hepatotoxicity and clinical safe medication of pexidartinib.
    Journal
    |
    UGT1A9 (UDP Glucuronosyltransferase Family 1 Member A9) • UGT1A6 (UDP Glucuronosyltransferase Family 1 Member A6) • UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)
    |
    Turalio (pexidartinib)
    11ms
    The kinase PLK1 promotes Hedgehog signaling-dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer. (PubMed, Sci Signal)
    Combining enzalutamide with the clinically approved Hh pathway inhibitor vismodegib inhibited cell growth and promoted apoptosis in enzalutamide-resistant cell cultures and xenografts in vivo. Our findings reveal a mechanism of PLK1-mediated enzalutamide resistance and suggest a potential therapeutic strategy to overcome this resistance in prostate cancer.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PLK1 (Polo Like Kinase 1) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)
    |
    Xtandi (enzalutamide) • Erivedge (vismodegib)
    1year
    Allelic variants in xenobiotic metabolism genes predict susceptibility and worse prognosis of urothelial bladder cancer. (PubMed, Pathol Res Pract)
    This study is a pioneer in evaluating these variants in a Latin American population from Brazil and confirms occupational pesticide exposure as a risk factor for UBC, mainly in genetically susceptible individuals. Furthermore, these variants may have additional clinical value for predicting susceptibility and prognostic stratification in patients with exposure-related cancers such as UBC.
    Journal
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)
    over1year
    Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by darolutamide: prediction of in vivo drug-drug interactions. (PubMed, Chem Biol Interact)
    In particular, it also potently inhibited SN-38, the active metabolite of irinotecan, glucuronidation in HLMs with an IC50 value of 3.84 ± 0.46 μM. The prediction results showed that darolutamide may increase the risk of DDIs when administered in combination with substrates of UGT1A1, UGT1A7, or UGT2B15. Therefore, the combined administration of darolutamide and drugs metabolized by the above UGTs should be used with caution to avoid the occurrence of potential DDIs.
    Preclinical • Journal
    |
    UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)
    |
    UGT1A1*1*1
    |
    irinotecan • Nubeqa (darolutamide)
    almost2years
    Inhibition of Human UDP-Glucuronosyltransferase Enzyme by Entrectinib: Implications for Drug-Drug Interactions. (PubMed, Chem Biol Interact)
    Furthermore, the results from quantitative prediction research suggested that the combination of entrectinib at 600 mg/day with substrates primarily metabolized by hepatic UGT2B15 or intestinal UGT1A7 and UGT1A8 might cause clinical DDIs. Thus, special attention should be paid to avoid adverse reactions induced by DDIs when co-administration of entrectinib and drugs metabolized by UGTs.
    Journal
    |
    UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15) • UGT1A8 (UDP Glucuronosyltransferase Family 1 Member A8)
    |
    Rozlytrek (entrectinib)
    almost2years
    Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience. (PubMed, Biomed Pharmacother)
    Real-world TIC incidence is higher compared to randomized clinical trials and biomarkers with potential predictive value aren't available. Our preliminary data, as proof of concept, could suggest a predictive role of pharmacogenomic approach in the identification of cardiotoxicity risk biomarkers for anti-HER2 treatment.
    Clinical • Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • SLC22A1 (Solute Carrier Family 22 Member 1) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • UGT1A6 (UDP Glucuronosyltransferase Family 1 Member A6) • UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)
    |
    UGT1A1*1*1
    |
    Herceptin (trastuzumab)
    2years
    Androgen Receptor/AP-1 Activates UGT2B15 Transcription to Promote Esophageal Squamous Cell Carcinoma Invasion. (PubMed, Cancers (Basel))
    Importantly, simultaneous blocking of AP-1 and AR resulted in stronger inhibition of cell invasiveness compared to inhibiting AP-1 or AR alone. In conclusion, our study reveals the molecular mechanisms underlying the AR-driven ESCC invasion and suggests that the AR/AP1/UGT2B15 transcriptional axis can be potentially targeted in suppressing metastasis in male ESCC patients.
    Journal
    |
    AR (Androgen receptor) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)
    over2years
    Exploring the Interplay Between Vitamin B-related Biomarkers, DNA Methylation, and Gene-Nutrition Interaction in Esophageal Precancerous Lesions. (PubMed, Arch Med Res)
    This study suggests that vitamin B depletion may be associated with aberrant DNA methylation and increased risk of EPL through the one-carbon metabolism pathway, presents that the TCN2 C776G polymorphism may interact with vitamin B nutritional status to affect EPL risk in males, and also identifies specific locations in the UGT2B15 and FGFR2 promoters with potential as promising molecular biomarkers.
    Journal • Epigenetic controller
    |
    FGFR2 (Fibroblast growth factor receptor 2) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)
    over2years
    Drug-drug interaction potentials of tucatinib inhibition of human UDP-glucuronosyltransferases. (PubMed, Chem Biol Interact)
    The quantitative prediction of DDIs risk indicated that the co-administration of tucatinib with drugs mainly metabolized by hepatic or intestinal UGTs (UGT1A1, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B15 and UGT2B17) might result in potential DDIs risk through inhibition of glucuronidation. More attention should be paid to the influence of tucatinib on UGTs in liver and intestine to avoid unnecessary clinical DDIs risk.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • UGT1A9 (UDP Glucuronosyltransferase Family 1 Member A9) • UGT1A6 (UDP Glucuronosyltransferase Family 1 Member A6) • UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15) • UGT2B17 (UDP Glucuronosyltransferase Family 2 Member B17) • UGT1A10 (UDP Glucuronosyltransferase Family 1 Member A10) • UGT1A3 (UDP Glucuronosyltransferase Family 1 Member A3) • UGT1A8 (UDP Glucuronosyltransferase Family 1 Member A8)
    |
    HER-2 positive • UGT1A1*1*1
    |
    Tukysa (tucatinib)
    almost3years
    High Expression of Ten Eleven Translocation 1 Is Associated with Poor Prognosis in Hepatocellular Carcinoma. (PubMed, Mediators Inflamm)
    TET1 was closely involved in immune infiltration and activation of oncogenic pathways. The DNA demethylation-related risk model was potential to be applied for predicting HCC prognosis in clinics.
    Journal • IO biomarker
    |
    SERPINH1 (Serpin family H member 1) • TET1 (Tet Methylcytosine Dioxygenase 1) • SLC1A5 (Solute Carrier Family 1 Member 5) • CDC20 (Cell Division Cycle 20) • SPHK1 (Sphingosine Kinase 1) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)